Technology Catalogue – University of Copenhagen

Forward this page to a friend Resize Print Bookmark and Share

Business Collaboration > Commercialisation > Technology Catalogue

Technology Catalogue

The University of Copenhagen (UCPH) owns a number of technologies, which external researchers and companies can purchase a license to use. Below are descriptions of some of the technologies that are currently available.

You are also welcome to contact the Tech Transfer Office to get a full overview of current inventions within a specific field of study.

Current licensing opportunities

Anti-counterfeiting system - Unbreakable physical encryption based on physical unclonable functions

Presented at the Danish IP Fair, May 2017

Counterfeit consumer goods, from designer bags to consumer electronics, introduce trillion dollar losses to industry and annually lead to the loss of thousands of jobs. This technology offers:

• Complete anti-counterfeiting protection (electronic components)
• Complete consumer protection towards falsified products (medicine/formula)
• Full brand protection (luxury goods)

Link: Read the full description

Patent application number: EP17152670.0

Contact:
Bo Stenhuus, Commercial Officer
Technology Transfer Office
E-mail: bo.stenhuus@adm.ku.dk
+45 2961 1382

Antibiotics against MRSA - Piperazine Inhibitors of Bacterial Gyrase and Topoisomerase IV

Presented at the Danish IP Fair, May 2017

A new class of synthetic antibiotics with excellent activity against Gram-positive bacteria and especially methicillin-resistant Staphylococcus aureus (MRSA) with slow resistance development compared to current drugs and promising hERG data. This new class of antibiotics possesses a simple chemical structure, which facilitates its rapid non costly preparation via chemical synthesis.

Link: Read the full description

Intellectual Property Rights: PCT patent application filed on March 2, 2016

Contact:
Peter Stein Nielsen, Commercial Officer
Technology Transfer Office
E-mail: Peter.nielsen@adm.ku.dk
+45 21 64 74 47

 

Antibody-drug conjugate (ADC) targeting the collagen receptor uPARAP

Presented at the Danish IP Fair, May 2017

Development of a novel drug for personalized therapy directed against sarcomas, glioblastoma and certain leukemias. These diseases are in urgent need for novel means of targeted treatment, and in many cases no curative option currently exists. In particular, among these diseases, this therapy is directed against primary bone cancer (osteosarcoma, a prominent cancer in young patients), and glioblastoma multiforme (the most malignant brain tumors). Additional, larger possible indications for treatment are e.g. breast cancer, prostate cancer and head- and neck cancer, where the target receptor has been demonstrated to be expressed by cells of the tumor stroma.

Link: Read the full description

Intellectual Property Rights: Priority founding patent application filed 5 February 2016 as PA 2016 70063. Novel data added October 2016 (PA 2016 70834) and in PCT application on February 03, 2017 (P4124PC00).

Contact:
Contact information
Niels Behrendt, Section head, D.Sc.
The Finsen Laboratory,
Rigshospitalet / BRIC, Univ. Cph., Denmark Tel.: (+45) 3545 6030
e-mail: niels.behrendt@finsenlab.dk

   

Co-amorphous mixtures - the solution to your solubility problems

Presented at the Danish IP Fair, May 2017

Powder performance is often limited by the poor solubility of compounds, for example in the fields of pharmaceutical and food sciences. Natural biomolecules can help solve this issue when used in a so-called co-amorphous mixture. A certain type of biomolecules have demonstrated exceptionally good properties in these mixtures and are considered safe, non-toxic and inexpensive to use in foods and medicines.

Link: Read the full description

Intellectual Property Rights: Danish priority application filed in December 2016

Contact:
Maj Hilligsøe, Commercial Officer
Technology Transfer Office
E-mail: maj.hilligsoe@adm.ku.dk
+45 35 32 63 32

 

Developing a Scalable Cell Therapy for Type 1 Diabetes

Presented at the Danish IP Fair, May 2017

We have identified a unique cell surface marker that allows purification of the beta cell progenitor cells. This in combination with their simplified method for producing stem cell derived insulin cells from these purified progenitor cells results in a safer and more efficient final product.

Link: Read the full description

Intellectual Property Rights: PCT application filed on April 21, 2016.

Contact:
Peter Stein Nielsen, Commercial Officer
Technology Transfer Office
E-mail: Peter.nielsen@adm.ku.dk
+45 21 64 74 47

 

Colonoscopy Preparation - A Novel Bowel Cleansing Product

Presented at the Danish IP Fair, May 2017

Using the collective insight, knowledge and wisdom of the team, a formulation which retains the key, recommended, ingredients of the existing product but that rather than representing a burden is actually palatable. (it looks, smells, tastes and looks like caramel-pudding The changes are expected, if anything, to reduce the main side effects associated with the existing products such as nausea and bloatedness (we can do little as to the resulting “diarrhea”).

Link: Read the full description

Intellectual Property Rights:
A patents application has been filed. Danish Application number: PA 2016 70326, Submission number 1400009518, Priority: 18 May 2016

Contact:
Bo Stenhuus, Commercial Officer,
Technology Transfer Office
E-mail: bo.stenhuus@adm.ku.dk
+45 2961 1382  

 

EMBARC - Engineering modulators of brown adipose receptors

Presented at the Danish IP Fair, May 2017

We are developing compounds that stimulate the calorie-burning and blood sugar-lowering actions of a unique organ called brown adipose tissue.

Link: Read the full description

Intellectual Property Rights:
Intellectual property rights: Danish priority application filed in December, 2016

Contact:
Peter Stein Nielsen, Commercial Officer
Technology Transfer Office
E-mail: Peter.nielsen@adm.ku.dk
+45 21 64 74 47

 

Finding new anticancer drugs - Novel HT-screening methodology for simultaneous identification of different classes of molecules

Presented at the Danish IP Fair, May 2017

Screening methods for the identification of novel chemotherapeutic drugs are either too unspecific (for instance plain cell viability) or too specific, relying on the development of a specific assay for a specific target. Here we present a methodology that allows the simultaneous identification of molecules belonging to different types of therapeutic targets in one single assay. This method is based on the multi-parameter analysis of replication stress markers, aiming at discovering new classes of successful chemotherapeutic drugs and novel compounds that kill cancer cells by replication stress.

Link: Read the full description

Intellectual Property Rights: WO2016078670

Contact:
Bo Stenhuus, Commercial Officer
Technology Transfer Office
E-mail: bo.stenhuus@adm.ku.dk
+45 2961 1382

 

Gene editing tool - Protein based genome editing tool

Presented at the Danish IP Fair, May 2017

Precise gene editing tools are very important in developing cells with novel properties. However it is unclear who has the intellectual rights to the tool such as Cas9/CRISPR. UCPH now has a new proprietary tool very suitable for precise gene editing BurrH. BurrH has several advantages over other emerging genome editing tools higher specificity, can be more easily fused with other peptides and enzymatic activities (e.g. nucleases, transcription factors). It is smaller than other gene editing tools such as TALAE and so it can be easier to transfect into a host cell.

Link: Read the full description

Intellectual Property Rights:
The invention is protected in a non-published patent application

Contact:
Bo Stenhuus, Commercial Officer
Technology Transfer Office
e-mail: Bo.stenhuus@adm.ku.dk 
+45 2961 1382

 

IBdetect: RNA-based diagnosis of inflammatory bowel disease

IBDetectTM is ideal for a ready-to-use diagnostic kit. It will reduce waste of healthcare resources and improve the quality of life for IBD patients.
• It is cheap and easy to implement – qPCR equipment is already widely available at hospitals
• It is quick to use – analysis can be completed within the same time frame as histological examination
• It can significantly increase the quality of IBD treatment without burdening the patient

Link: Read the full description

Intellectual Property Rights:
A priority patent application was filed on 07 July 2017.

Contact:
Liv Søndergaard Thomsen, Commercial Officer
Technology Transfer Office
E-mail: liv.thomsen@adm.ku.dk
+45 2057 0297  

 

Immortalized cell culture of ER-positive human breast epithelial cells

Researchers at the University of Copenhagen have developed a viable breast cell culture system expressing endogenous estrogen receptors for use in clinical and basic research.

The researchers have used immortalized ER-positive human breast cells and thereby allowing for both long term study and screening of drug candidates. Understanding the taxonomy and evolution of breast cancer rely on using normal cell types as a reference; however in current cell cultures the steroid receptor expression from normal breast cells is lost within a few days. There is a need for a viable breast cell culture system expressing endogenous estrogen receptors for use in clinical and basic research.

The assay for investigating normal breast cells involves isolating and tracking ER-positive human breast cells by FACS, using certain cell markers and releasing ER-positive cells from growth restraint by using inhibitors of TGF-β signaling.

Link: Read the full description.

Patent Application Number: PA 2015 70274

Contact: Maj Hilligsøe, Commercial Officer  

Improved Biofuel Production - using Smart Algae

Presented at the Danish IP Fair, May 2017

Interested in improving bioethanol production derived from plant biomass and/or new microalgal biotechnology? Then this invention is for you. We have generated unique microalgal strains capable of optimizing the digestion of lignocellulosic biomass permitting improved production of ethanol while significantly reducing the production cost.

Link: Read the full description

Intellectual Property Rights: Danish priority application filed 2016

Contact:
Maj Hilligsøe, Commercial Officer
Technology Transfer Office
e-mail:maj.hilligsoe@adm.ku.dk
+45 35 32 63 32

 

Light-driven enzymes - Enzyme systems that runs on solar energy

Presented at the Danish IP Fair, May 2017

A new and unique way of boosting oxidative enzymes by the use of light has been discovered. By simply combing a monooxygenase enzyme with pigments e.g. derived from chlorophyll, and exposing them to light, the activity of the enzymes can be increased up to hundredfold. This makes it possible to oxidize otherwise hard to degrade carbohydrates such as cellulose as well as hemicellulose, starch and potentially keratin. The technology may also be developed for light-driven oxidation of methane to methanol. The potential of directly using the energy of light to drive biochemical reactions opens a new world of production technologies and products

Link: Read the full description

Intellectual Property Rights:
The invention is covered by PCT patent application PCT/EP2016/066804 filed 14 July 2016

Contact:
Niels Lysholm Engelhard, Senior Commercial Officer
Technology Transfer Office
E-Mail: nien@adm.ku.dk
+45 2875 6330

 

Lipid-Polymer Hybrid Nanoparticles for Oligonucleotide Delivery - An innovative and efficient platform technology for local and systemic delivery

Presented at the Danish IP Fair, May 2017

Thermostable and inhalable dry powder formulation of lipidoid-polymer hybrid nanoparticles (LPNs) for efficient local and/or systemic delivery of oligonucleotides, e.g. siRNA, and single stranded antisense oligonucleotides.

Link: Read the full description

Intellectual Property Rights:
A European patent application has been filed on March 17, 2016 and PCT update on March 16, 2017

Contact:
Peter Stein Nielsen, Commercial Officer
Technology Transfer Office
E-mail: Peter.nielsen@adm.ku.dk
+45 21 64 74 47


 

MABs Targeting ADAM12 in Cancer - A novel approach to anti-invasive and anti-metastatic treatment

Presented at the Danish IP Fair, May 2017

By using monoclonal antibodies targeting ADAM12 it is possible to prevent metalloprotease MT1-MMP (MMP14)-mediated degradation of the cellular matrix (ECM). Thus, ADAM12 represents a target for anti-invasive and anti-metastatic treatment, which remains an underexplored field in cancer treatment. ADAM12 is expected to be a good cancer drug target because it is expressed at very low levels in normal adult tissues. Yet, it is upregulated upon tissue injury or excessive growth as seen in cancer or re-generation.

Link: Read the full description

Intellectual Property Rights: PCT application: WO 2015028027

Contact:
Ole Wiborg, Consulting Commercial Officer
E-mail: ow@wiborg.com
+45 40 96 80 18

 

Method for increasing protein stability and small molecular API solubility

The University of Copenhagen has developed a novel method of drastically increasing the thermal stability of protein, allowing for heating to 121 degrees Celcius without visible aggregation.

Problems of solubility and stability of novel small molecule drug candidates and novel protein/peptide based drug candidates may reduce drug efficacy, and induce toxicity or immunogenicity as well as increasing production costs, and thereby risking that novel treatments never reach the market.

The new technology, which implies addition of non-cytotoxic nanoparticles to the formulation, leads to increased protein thermal stability and significantly increases solubility of poorly soluble APIs. This non-cytotoxic, low cost method requires no additional steps and may be used in any formulation.

Link: Read the full description.

Patent Application Number: PCT/DK2015/188838 and PA 2014 70354

Contact: Maj Hilligsøe, Commercial Officer  

Modulators of Fast Synaptic Inhibition - New peptide based compounds act on Gephyrin to modulate GABAergic Transmission

Presented at the Danish IP Fair, May 2017

Potential pharmacological treatment of mental disorders by a unique and conceptually novel mode of action. Our peptides are highly subtype-specific and do not interfere with normal receptor function.

Link: Read the full description

Intellectual Property Rights:
CT patent application nr. PCT/DK2016/050369 filed on 16 November 2016. The University of Copenhagen holds all the rights to the invention.

Contact:
Liv Søndergaard Thomsen, Commercial Officer
Technology Transfer Office
E-mail: liv.thomsen@adm.ku.dk
+45 2057 0297

 

Novel principles for osteoporosis treatment

Presented at the Danish IP Fair, May 2017

• Dual receptor agonist
• Small peptide backbone
• High potency
• High specificity

Based on published and unpublished data of ligand binding-modes to the GIP and GLP-2 receptors, we were able to develop GIPR/GLP-2R co-agonists of which the best two had potencies of maximum 6-fold difference compared to the native hormones on these two receptors.

Link: Read the full description

Intellectual Property Rights: Danish priority patent application filed on October 12, 2016

Contact:
Peter Stein Nielsen, Commercial Officer
Technology Transfer Office
E-mail: Peter.nielsen@adm.ku.dk
+45 21 64 74 47


 

β-Bodies - antibody mimetics with ultrahigh affinity and specificity

Presented at the Danish IP Fair, May 2017

The technology will enable a licensee to provide customized antibody equivalents designed to recognize almost any surface of a protein.

Link: Read the full description

Intellectual Property Rights: Danish patent application filed in November 2016

Contact:
Michael Abildgren, Commercial Officer
Technology Transfer Office
E-mail: michael.abildgren@adm.ku.dk
+45 35 33 22 85

 

Pollution Control Using Ozone - Inexpensive New Method for Cleaning Hot Exhaust air

A new method for cleaning a polluted airstream using thermal breakdown products of ozone. The air to be cleaned and ozone is passed over a reaction surface at a temperature sufficient to cause formation of said breakdown products and oxidation of polluting compounds in the air-stream by the breakdown products. The mechanism is currently not known but no oxidation catalyst is involved in the process.

Link: Read the full description

Intellectual Property Rights: DPCT/EP2017/064787

Contact:
Niels Lysholm Engelhard, Senior Commercial Officer
Technology Transfer Office/RegionH
E-mail: nien@adm.ku.dk
+45 28 75 63 30

 

Restriction Enzymes v2.0 – New set of restriction enzymes.

Presented at the Danish IP Fair, May 2017

Restriction enzymes (REs) are vastly used in many fields in science from traditional cloning experiments to DNA mapping. There are 2 major limitations in the canonical REs

1. each REs recognize one specific sequence, and while the number of these enzymes is quite large they are not yet enough to recognized all possible DNA sequences.

2. each canonical REs is a different proteins, and although many of them are produced recombinantly, each REs require some adjustments in the production to maximise the yield, this will ultimately affect the cost of the products. UCPH now has a new proprietary tool to generate RE version 2.0 that do not have these limitations.

This new class of REs is made of a constant protein part (Cpf1), and of a variable RNA part that will provide the DNA specificity to the enzyme. The assembled of these two components will produce enzymes able to cut any user-defined DNA sequences. Furthermore,  in this RE-2.0, because the RNAs are quite short (42 bases) their production is very easy and standard. This together with the fact that the protein, Cpf1 is the same in all enzymes, will allow the production of all the RE-2.0 with a single protocol and at the same cost.

Link: Read the full description

Intellectual Property Rights: The invention is protected in a non-published patent application

Contact:
Bo Stenhuus, Commercial Officer,
Technology Transfer Office
E-mail: bo.stenhuus@adm.ku.dk
+45 2961 1382

 

Targeting TONSL for cancer therapy - Structure-based design of novel small molecule inhibitors

Presented at the Danish IP Fair, May 2017

Under a pre-seed grant from the Novo Nordisk Foundation we are working with external partners in USA, Canada and France on designing and syntesizing novel small molecule inhibitors. In parallel, we are aiming at validating TONSL as a clinically relevant cancer target through a number of in-vitro and in-vivo screens of cells and animal models. The focus is to determine what type of cancers could benefit most from treatment with TONSL inhibitors.

Link: Read the full description

Intellectual Property Rights:
Intellectual property rights: PCT application submitted 2016

Contact:
Structure based drug design - Thomas Frimurer (KU)
Ole Wiborg, Consulting Commercial Officer
ow@wiborg.com
+45 40 96 80 18

 

Therapy for IBD - Rectal therapy with compound X – an investment opportunity

Presented at the Danish IP Fair, May 2017

We have invented a novel therapeutic principle for treatment of inflammatory bowel disease and the therapy is especially well suited for the treatment of ulcerative colitis. The current state-of-the-art therapy for IBD targets the immune system and involves the uses of 5-aminosalicylates, steroids, thiopurines and biological therapies such as e.g. anti-tumor necrosis factor alpha antibodies.

The unique properties of the therapy are:

• Based on the repurposing of a known substance – compound X
• Targeting the epithelium rather than the immune system
• Anti-tumorigenic effect in the

Link: Read the full description

Intellectual Property Rights: EP priority patent application filed on November 14, 2016

Contact:
Peter Stein Nielsen, Commercial Officer
Technology Transfer Office
E-mail: Peter.nielsen@adm.ku.dk
+45 21 64 74 47

 

Treatment of paediatric pain - Strong niche product protected by regulatory data protection

Presented at the Danish IP Fair, May 2017

The maturity level of the overall project corresponds to TRL 6/TRL 7. The nasal spray has been investigated in a clinical trial in 50 paediatric patients with encouraging results in respect to efficacy as well as safety. Moreover, the product was well accepted by the patients. The remaining development, including the overall strategy is currently discussed with the European Medicines Agency and we expect to reach an agreement with the authorities on the paediatric development plan by Q4, 2017.

Link: Read the full description

Intellectual Property Rights: All rights belong to Copenhagen University Hospital, Rigshospitalet.

Contact:
Lars.noergaard@childtreat.dk; Phone: +45 2612 5010

louise.meinert@adm.ku.dk; Phone: +45 3533 0334

 

Unique or Custom Probes - Exclusive or made-to-order fluorescent dyes KU-dyes.com

Presented at the Danish IP Fair, May 2017

Dyes are high value products. KU dyes operate on three tracks. The first is by exploiting the new unique probes exclusive to KU Dyes (IP protected). The second is to build value through documentation, supplying dyes for products in regulated markets. The third is establishing new product lines through individual R&D projects.

Link: Read the full description

Intellectual Property Rights:
20 /1/2016 - Substituted acridine-like and xanthenium-like fluorescent dyes PCT/DK2016/0

Contact:
KU Dyes ApS,
Universitetsparken 5,
2100 København Ø
E-mail: BWL@ku-dyes.com / TJS@ku-dyes.com 
+45 28 569 557
www.ku-dyes.com